Albert Bourla assumed the role of chief executive officer at Pfizer in 2019, fundamentally shifting the corporation toward an aggressive focus on pharmaceutical research and development. A veterinarian by original training, his tenure has been marked by significant global acquisitions and the rapid scaling of vaccine production during the COVID-19 pandemic, reshaping the company's long-term business strategy.
Academic and Early Professional Roots
Born in Thessaloniki in 1961 to Sephardi Jewish parents, Bourla pursued his education at the Aristotle University of Thessaloniki. He earned his doctorate in veterinary medicine in 1985 and completed his Ph.D. in the biotechnology of reproduction in 1991. His early career began in Greece in 1993, where he joined Pfizer as a technical director for the animal health division.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →Rising Through the Pfizer Ranks
Bourla immigrated to the United States in 2001 after a series of promotions. His career path included leading the animal health division in Europe, Africa, and the Middle East, as well as managing regional integration following the merger with Wyeth's Fort Dodge business. By 2014, he moved into the human pharmaceutical sector, overseeing global vaccines and oncology, where he managed the launches of drugs such as Eliquis and Ibrance. He served as chief operating officer before succeeding Ian Read as CEO.
Corporate Strategy and Acquisitions
As CEO, Bourla prioritized scientific innovation by divesting non-core business units, including the consumer healthcare business Haleon. Under his leadership, the company pursued significant expansion, most notably the 2023 acquisition of biotechnology firm Seagen for $43 billion, which expanded the firm's oncology portfolio. In 2025, he announced a $10 billion acquisition of Metsera to target metabolic and obesity treatments, with plans for upcoming GLP-1 receptor agonist therapies.
Pandemic Leadership and Awards
During the 2020 global health crisis, Bourla directed the development of the Pfizer–BioNTech COVID-19 vaccine, opting to fund production before formal regulatory approval. This leadership was documented in his 2022 book, Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible. His professional impact earned him the 2022 Genesis Prize, the Bower Award for Business Leadership, and the Gold cross of the Order of the Redeemer.
Fast facts
- Born: 1961, Thessaloniki, Greece
- Education: Aristotle University of Thessaloniki
- Professional Background: Veterinarian, pharmacologist, executive
- Joined Pfizer: 1993
- Appointed CEO: 2019
- Notable Awards: Genesis Prize, Bower Award for Business Leadership
- Languages: English, Modern Greek
Questions readers ask
What was Albert Bourla's academic specialization?
He holds a doctorate in veterinary medicine and a Ph.D. focused on the biotechnology of reproduction.
Which major acquisitions occurred during his tenure as CEO?
Key acquisitions include the $43 billion purchase of Seagen in 2023 and the $10 billion acquisition of Metsera in 2025.
Achievements
- Affiliated with Pfizer
- Educated at Aristotle University of Thessaloniki
- Worked as business executive, pharmacologist and veterinarian
